Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
McKinsey
Moodys
Dow
Colorcon

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for CRLX101

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for CRLX101?

CRLX101 is an investigational drug.

There have been 12 clinical trials for CRLX101. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2012.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Cerulean Pharma Inc., National Cancer Institute (NCI), and City of Hope Medical Center.

There are four US patents protecting this investigational drug and twenty-three international patents.

Recent Clinical Trials for CRLX101
TitleSponsorPhase
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentNational Cancer Institute (NCI)Phase 2
Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1/Phase 2
Alternative Dosing for CRLX101 Alone, With Avastin and With mFOLFOX6 in Advanced Solid TumorsCerulean Pharma Inc.Phase 1

See all CRLX101 clinical trials

Clinical Trial Summary for CRLX101

Top disease conditions for CRLX101
Top clinical trial sponsors for CRLX101

See all CRLX101 clinical trials

US Patents for CRLX101

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CRLX101   Start Trial Camptothecin analogs and methods of preparation thereof University of Pittsburgh (Pittsburgh, PA)   Start Trial
CRLX101   Start Trial Camptothecin analogs and methods of preparation thereof University of Pittsburgh (Pittsburgh, PA)   Start Trial
CRLX101   Start Trial Camptothecin analogs and methods of preparation thereof University of Pittsburgh--of the Commonwealth System of Higher Education (Pittsburgh, PA)   Start Trial
CRLX101   Start Trial Camptothecin analogs and methods of preparation thereof University of Pittsburgh - of The Commonwealth System of Higher Education (Pittsburgh, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CRLX101

Drugname Country Document Number Estimated Expiration Related US Patent
CRLX101 Austria 418338 2017-08-29   Start Trial
CRLX101 Australia 3123600 2017-08-29   Start Trial
CRLX101 Australia 760543 2017-08-29   Start Trial
CRLX101 Australia 777786 2017-08-29   Start Trial
CRLX101 Australia 8476198 2017-07-02   Start Trial
CRLX101 Australia 9205698 2017-08-29   Start Trial
CRLX101 Canada 2302226 2017-07-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
McKinsey
Dow
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.